Related Experiment Video

Updated: Jun 20, 2026

Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR
07:24

Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR

Published on: April 8, 2013

Regression of left ventricular mass by antihypertensive treatment: a meta-analysis of randomized comparative studies

Robert H Fagard1, Hilde Celis, Lutgarde Thijs

  • 1Hypertension and Cardiovascular Rehabilitation Unit, Faculty of Medicine, University of Leuven KU Leuven, Leuven, Belgium. robert.fagard@uz.kuleuven.ac.be

Hypertension (Dallas, Tex. : 1979)
|September 23, 2009
PubMed

Insights

Beta-blockers show less left ventricular mass regression compared to other antihypertensives. Angiotensin receptor blockers may offer greater regression, though beta-blockers

Area of Science:

  • Cardiology and Hypertension Research
  • Pharmacological Interventions
  • Cardiac Remodeling Studies

Background:

  • Blood pressure management is crucial for reducing left ventricular mass.
  • Previous studies have not definitively compared the impact of different antihypertensive drug classes on left ventricular mass regression.
  • Understanding these differences is vital for optimizing hypertension treatment strategies.

Purpose of the Study:

  • To compare the efficacy of various antihypertensive drug classes in regressing left ventricular mass.
  • To investigate potential differences in left ventricular mass reduction among diuretics, beta-blockers, calcium channel blockers, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers.
  • To identify factors influencing left ventricular mass regression through meta-regression analysis.

Main Methods:

  • Systematic meta-analysis of prospective, randomized comparative studies.
  • Involved pooled pairwise comparisons between drug classes and pooled comparisons against other classes combined.
  • Utilized meta-regression analysis to explore determinants of left ventricular mass regression.

Main Results:

  • Analysis of 75 publications and 6001 patients revealed significant differences in left ventricular mass regression.
  • Beta-blockers demonstrated significantly less regression (9.8%) compared to angiotensin receptor blockers (12.5%).
  • Beta-blockers showed less regression than the other four drug classes combined, while angiotensin receptor blockers showed more pronounced regression.

Conclusions:

  • Beta-blockers are associated with reduced left ventricular mass regression compared to other antihypertensive agents.
  • Angiotensin receptor blockers may induce greater left ventricular mass regression.
  • The inferiority of beta-blockers in this regard appears more robustly demonstrated than the superiority of angiotensin receptor blockers.

Related Concept Videos

Aortic Regurgitation III: Medical Management01:25

Aortic Regurgitation III: Medical Management

Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
Mitral Regurgitation III: Medical Management01:25

Mitral Regurgitation III: Medical Management

Mitral regurgitation (MR) is characterized by retrograde blood circulation from the left ventricle into the left atrium due to inadequate mitral valve closure. The severity of the condition, symptoms, and underlying cause determine treatment strategies.Monitoring and Pharmacological TreatmentPatients with mild to moderate MR typically do not need immediate intervention but regular monitoring to assess progression and guide treatment. Patients with mild MR should have an echocardiogram every 3-5...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Hypertension III: Clinical Manifestations and Diagnostic Studies01:30

Hypertension III: Clinical Manifestations and Diagnostic Studies

Hypertension is asymptomatic and also referred to as the "silent killer" until it progresses to a severe stage or causes target organ disease. Patients may experience symptoms stemming from the strain on blood vessels and tissues in various organs or the heart's increased workload.Physical exams might show no abnormalities other than high blood pressure. Signs of vascular damage, when present, correspond to the organs supplied by the affected vessels, leading to target organ damage. For...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Hypertension IV: Drug Therapy and Lifestyle Modifications01:28

Hypertension IV: Drug Therapy and Lifestyle Modifications

Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...